top of page
Search
All Posts
What are MPNs?
Diagnosed with MPN?
Living with MPNs
Women
Teens & Children
Events
MPN News
MPN Stories
Clinical Trials
Worldwide Day
Wellbeing
Dietary Main Course
You Tube Channel
Dietary Breakfast
Webinars
Global MPN Symposium
Novartis to Strengthen Oncology Pipeline with Agreement to Acquire MorphoSys AG, Including Late-Stage BET Inhibitor Pelabresib for Myelofibrosis (MF)
MPN NEWS
Peter Löffelhardt
Feb 6, 2024
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
MPN NEWS
Peter Löffelhardt
Feb 1, 2024
Rusfertide's REVIVE Study Highlights 2-Year Efficacy in Polycythemia Vera (PV)
CLINICAL TRIALS
Peter Löffelhardt
Jan 18, 2024
Navitoclax in Myelofibrosis: Investigational Treatment by AbbVie
CLINICAL TRIALS
Peter Löffelhardt
Dec 5, 2023
Pelabresib Phase 3 Trial Shows Significant Spleen Volume Reduction in Myelofibrosis
CLINICAL TRIALS
Peter Löffelhardt
Nov 21, 2023
Rusfertide Meets Primary Endpoint in Clinical Trial for PV patients
CLINICAL TRIALS
Peter Löffelhardt
Sep 26, 2023
1
2
3
4
5
Home
bottom of page